

**List of expert advisory panel members and declarations of interest**

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Tessa Lewis (Chair)	General Practitioner, Aneurin Bevan University Health Board	Direct, financial	GP partner	1995 - present	Declare and participate. Interest is non-specific
Dr Tessa Lewis (Chair)	General Practitioner, Aneurin Bevan University Health Board	Direct, financial	Medical adviser to PHE Primary care interventions unit (1 session per week)	Sept 2019 – present	Declare and participate. Interest is non-specific
Dr Imogen Locke	Consultant Oncologist (Breast and Lung), Royal Marsden Hospital	Direct, financial	Delivers Private Practice at Royal Marsden. Private work matches NHS practice, no systemic therapy is given in private practice and has no direct relation to SACT guidance. Approximately 5-10% private work undertaken	2011 – present	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Member of the Leadership Development in Postgraduate Medical Training National Leads Group, Health Education England. Honorarium received.	April 2018 - present	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Standing lay member: NICE Shared Decision-Making Guideline Committee. Honorarium received.	November 2018 – (anticipated end Dec 2020)	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Standing lay member: NHS Same Day Emergency Care Programme Board. Honorarium received	Aug 2019 - present	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Standing lay member: NICE Managing Common Infections Committee	Dec 2016 - present	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Member Northern Gas Networks Customer Engagement Group reviewing and overseeing the development of the Regulated Business Plan for 2021 to 2025	Sept 2018 - present	Declare and participate. Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Specialist lay member: NICE Diagnostics Advisory Committee – Rapid Tests for Group A Streptococcal Infection in People with a Sore Throat	Oct 2018 – Aug 2019	Declare and participate. Interest is non-specific

<b>Name</b>	<b>Job title and organisation</b>	<b>Type of interest</b>	<b>Description of interest</b>	<b>Relevant dates</b>	<b>Comments</b>
Ms Carole Pitkeathley	Lay member	Direct, financial	Consultancy work Health Education England Leadership Academy. Developing/reviewing leadership development programmes, evaluating internal and external evaluation processes and practices and evaluating individual programmes and funds. Paid consultancy rate.	Aug 2018 – Dec 2019 possibility of future work	Declare and participate.  Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Expert advisory panel member: COVID-19 Rapid Guidelines Expert Panel Vitamin D. Paid Honorarium	Nov – Dec 2020	Declare and participate.  Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Member of NICE Steering Group for the development of the Expert Panel. Paid Honorarium	Oct 2020 - present	Declare and participate.  Interest is non-specific
Ms Carole Pitkeathley	Lay member	Direct, financial	Member of Development Team for the development of a trial examining the use of antibiotics in urgent dental care. Paid honorarium	Nov 2020 – present	Declare and participate.  Interest is non-specific
Dr Peter Hampshire	Consultant in Anaesthesia and Intensive Care Medicine, Clinical Director for Intensive Care and Pain Services. Liverpool University Hospitals NHS Trust	Non-financial professional and personal	Specialist member of NICE Adviser panel on point of care testing for acute pancreatitis	Oct 2019 - present	Declare and participate.  Interest is non-specific
Dr Peter Hampshire	Consultant in Anaesthesia and Intensive Care Medicine, Clinical Director for Intensive Care and Pain Services. Liverpool University Hospitals NHS Trust	Non-financial professional and personal	Specialist contributor to HCID-A guidance on use of CPAP and NIV for respiratory failure in COVID-19	March 2020 – May 2020	Declare and participate.  Interest is non-specific
Professor David Baldwin	Consultant Respiratory Physician, Nottingham University Hospital	Direct, financial	Acted as Chair or presented at the following webinars on the COVID-19 response in the context of early diagnosis and CT screening for lung. There was no overlap with the SACT guidance update.	As below	Declare and participate.  Interest is non-specific
Professor David Baldwin	Consultant Respiratory Physician, Nottingham University Hospital	Direct, financial	Honorarium for non-promotional webinar Astra Zeneca.	June 2020	Declare and participate.  Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Professor David Baldwin	Consultant Respiratory Physician, Nottingham University Hospital	Direct, financial	Honorarium for non-promotional webinar MSD	July 2020	Declare and participate.  Interest is non-specific
Professor David Baldwin	Consultant Respiratory Physician, Nottingham University Hospital	Direct, financial	Honorarium for non-promotional webinar Roche	Dec 2020	Declare and participate.  Interest is non-specific
Professor David Baldwin	Consultant Respiratory Physician, Nottingham University Hospital	Direct, financial	Honorarium for non-promotional webinar Bristol Myers Squibb	Dec 2020	Declare and participate.  Interest is non-specific
Dr Deepak Mannari	Consultant Haematology, Somerset Foundation Trust	Direct, financial	Honorarium for attendance at Expert Review Meeting - Pfizer.	Sept 2019	Declare and participate.  Interest is non-specific
Dr Deepak Mannari	Consultant Haematology, Somerset Foundation Trust	Direct, financial	Honorarium for attendance at Regional Myelofibrosis Advisory Board - Novartis	Sept 2019	Declare and participate.  Interest is non-specific
Dr Deepak Mannari	Consultant Haematology, Somerset Foundation Trust	Direct, financial	Honorarium for Expert Speaking Engagement on AML - Novartis	Sept 2019	Declare and participate.  Interest is non-specific
Dr Deepak Mannari	Consultant Haematology, Somerset Foundation Trust	Direct, financial	Private practice, clinical mirrors NHS practice, approximately 5% of clinical work is private practice.	June 2022	Declare and participate.  Private practice is limited and not specific to update in August 2022.
Professor Timothy Iveson	Professor of Gastro-intestinal Oncology, Southampton University	Direct, financial	Chief Medical Editor Macmillan	2014 – present	Declare and participate.  Interest is non-specific
Professor Timothy Iveson	Professor of Gastro-intestinal Oncology, Southampton University	Direct, financial	Attendance at a one-day event, Advisory Board Bristol Myers Squibb and honorarium received. There was no overlap with the SACT guidance update	Sept 2019	Declare and participate.  Interest is non-specific
Professor Timothy Iveson	Professor of Gastro-intestinal Oncology, Southampton University	Direct, financial	Speaker at a single Pierre Fabre meeting, honorarium received. There was no overlap with the SACT guidance update	Oct 2019	Declare and participate.  Interest is non-specific
Professor Timothy Iveson	Professor of Gastro-intestinal Oncology, Southampton University	Non-financial professional and personal	Medical Advisory Board Bowel Cancer UK	2016 – present	Declare and participate.  Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Suzanne Halliday (member from May 2022)	Advanced Nurse Practitioner, Surrey and Sussex Healthcare NHS Trust	Non-financial professional and personal	Published Review: A quality improvement project evaluating the application of a primary care referral screening tool for patients presenting to their GP with breast pain Suzanne Halliday, C. Zammit, K. Preston, U. Tse, L. Sewers, S. Bell, Z. Heyre, N. Groves, S. O'Brien, H. Green, D. Bloomfield, A. Mancey-Barratt  <a href="https://www.ejso.com/article/S0748-7983(21)00336-X/ppt">https://www.ejso.com/article/S0748-7983(21)00336-X/ppt</a>	2021	Declare and participate.  Interest is non-specific
Professor Robert Huddart	Consultant Clinical Oncologist, Royal Marsden Hospital	Direct, financial	Private practice Royal Marsden and Cancer Centre London, Parkside. Private practice matches NHS practice and accounts for approximately 20% of workload	1998 – present	Declare and participate.  Interest is non-specific
Professor Robert Huddart	Consultant Clinical Oncologist, Royal Marsden Hospital	Direct, financial	Partnership at Cancer Centre London LLP. Delivers private care matching NHS practice and is involving in managing the centre. Accounts for around 5 – 10% of workload.	2013 – to present	Declare and participate.  Interest is non-specific
Professor Robert Huddart	Consultant Clinical Oncologist, Royal Marsden Hospital	Direct, financial	Remunerated advisory boards and/or trial steering groups for Roche, Janssen, MSD, Nektar, Astellas and Bristol Myers Squibb in last 5 years. Most of the advisory boards related to the use of immune or targeted agents in care of bladder cancer and no remunerated activities since starting the guideline	2015 - 2020	Declare and participate.  Interest is non-specific
Professor Robert Huddart	Consultant Clinical Oncologist, Royal Marsden Hospital	Direct, financial	Speakers bureau Roche Janssen. Most of the involvement is related to the use of immune or targeted agents in care of bladder cancer and no remunerated activities since starting the guideline	2018 – 2020	Declare and participate.  Interest is non-specific
Professor Robert Huddart	Consultant Clinical Oncologist, Royal Marsden Hospital	Direct Financial	Chaired launch meeting of new immunotherapy treatment for Pfizer (remunerated)	May 2022	Declare and participate.  Interest is non-specific
Professor Ann Thomas (Member since May 2022)	Professor of Cancer Therapeutics and Honorary Consultant in Medical Oncology, University of Leicester	Non-financial professional and personal	I was involved in this audit and am a co-author on this paper: Lee RJ, Wysocki O, Bhogal T, Shotton R, Tivey A, Angelakas A, Aung T, Banfill K, Baxter M, Boyce H, et al. Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO open 6(1):100005 27 Nov 2020  This was a non-funded piece of work with a group of academics. The objective was to find potential prognostic biomarkers for covid outcome in cancer patients and then try and develop a predictive model. There is a follow up paper in preparation. Personally I see this as adding to my expertise in understanding Covid in cancer patients rather than a direct COI.  <a href="https://pubmed.ncbi.nlm.nih.gov/33399072/">https://pubmed.ncbi.nlm.nih.gov/33399072/</a>	April 2022  Ongoing	Declare and participate  Interest is specific but not included in the evidence base for SACT 2022 update  The content was not deemed to prejudice the panel member from approaching the evidence objectively.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Professor Ann Thomas (Member since May 2022)	Professor of Cancer Therapeutics and Honorary Consultant in Medical Oncology, University of Leicester	Non-financial professional and personal	<p>I am Director of the Hope Cancer Trials Centre in UHL NHS Trust and as such my staff have recruited participants to RemCap and Siren (I am a participant myself in the Siren study). I personally was not on the delegation log for RemCap and had no direct role.</p> <p>These are both national studies:  <a href="https://snapsurvey.phe.org.uk/siren/">https://snapsurvey.phe.org.uk/siren/</a> - this is recruiting healthcare workers to detect Covid incidence. It is observational and as a participant I complete questionnaires, have testing both PCR and antibody blood tests. The purpose of this study is to understand whether prior infection with SARS-CoV2 (the virus that causes COVID-19) protects against future infection with the same virus.</p> <p><a href="https://www.remapcap.org/">https://www.remapcap.org/</a> - REMAP-CAP uses a novel and innovative adaptive trial design to evaluate a number of treatment options simultaneously and efficiently. This design is able to adapt in the event of pandemics and increases the likelihood that patients will receive the treatment that is most likely to be effective for them. I am not directly involved with this study although my cancer research nurse team was redeployed into the trust to deliver this study.</p>	Start: 01/04/2022  Ongoing	Declare and participate  Interest is non-specific